Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/4743
Nаziv: | A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer? | Аutоri: | Sreter K. Jakopovic M. Janevski Z. Samarzija M. Zarogoulidis P. Kioumis I. Mparmpetakis N. Pataka A. Zarogoulidis K. Tsiouda T. Kosmidis C. Mpaka S. Huang H. Hohenforst-Schmidt W. Charalampidis C. Machairiotis N. Bojan Zarić Aleksandar Milovančev |
Ključnе rеči: | Pleural effusion (malignant);lung neoplasms;mitoxantrone;pleurodesis;feasibility studies | Dаtum izdаvаnjа: | 1-мај-2016 | Čаsоpis: | Annals of Translational Medicine | Sažetak: | © Annals of Translational Medicine. All rights reserved. Background: Lung cancer is the leading cause of malignant pleural effusion (MPE). Management of MPEs remains a clinical challenge due to recurrence and poor quality of life. An ideal sclerosing agent has yet to be found. The aim of this cohort pilot study was to evaluate the role of mitoxantrone pleurodesis (MP) as an alternative to talc sclerotherapy for managing MPEs in lung cancer patients. Methods: A retrospective chart review was conducted on consecutively admitted patients with MPE to the Department of Post-Intensive Care at the Clinic for Respiratory Diseases "Jordanovac", University Hospital Centre Zagreb, in Croatia. Results: Of 34 patients with MPE, twenty-one (64.8±9.46 years; 47-84 years) with primary lung carcinoma who received MP (30 mg of mitoxantrone) between December 2003 and February 2009 were included in this study. Chest radiographs taken prior to sclerotherapy and at 1-, 2-, and 3-month follow-up were compared. At the postsclerotherapy evaluation periods, overall success (OS) rates of MP were 88.2% [17.6%, complete response (CR); 70.6%, partial response (PR)], 53.9% (7.7% CR; 46.2% PR), and 45.5% (PR), respectively. Kaplan-Meier median survival from MP until death was 5.2 months, while that from diagnosis of primary lung cancer was 12.3 months. Conclusions: MP may be a safe and effective method of managing MPE due to lung cancer. Future randomized controlled studies comparing mitoxantrone and talc pleurodesis in lung cancer patients are warranted to elucidate whether a significant difference exists between these agents. Factors affecting success, survival probability, and quality of life also require further investigation. | URI: | https://open.uns.ac.rs/handle/123456789/4743 | ISSN: | 23055839 | DOI: | 10.21037/atm.2016.04.15 |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
1
prоvеrеnо 03.05.2024.
Prеglеd/i stаnicа
22
Prоtеklа nеdеljа
10
10
Prоtеkli mеsеc
0
0
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.